Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 ...
BEIJING (Reuters) -China will suspend port fees levied on U.S.-linked vessels for a year, its transport ministry said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback